Aripiprazole
For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.
Active substance: Aripiprazole
Examples of brand names: Abilify [EU/DE]
ATC code: N05AX12
Main use (for orientation): Schizophrenia; bipolar disorder
Documented research summary
Suspected QTc/tachycardia case with THC-rich cannabis; causality limited. CBD attenuated aripiprazole effects in a rat model, without human confirmation. Cannabis/Delta8 psychosis treatment and cannabis use disorder registry data do not confirm safe co-use.
Uncertainties and limitations
Oral single-ingredient tablet, not the lauroxil prodrug or long-acting injection. Registry long-acting injections identified separately.
Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.
Separately recorded findings
4 separately recorded findings. Each statement applies to its documented study context.
THC-rich cannabis (18% THC, 1% CBD) – clinical signals
Finding ID: B0320
Type of result: Suspected clinical signal during multiple-drug treatment
Observation: QTc 560 ms and ventricular tachycardia reported.
Mechanism: Suspected case; pharmacokinetic explanation hypothetical
Study type: Retrospective reporting series; one aripiprazole case
Context studied: 55-year-old man, aripiprazole 30 mg/day, pregabalin and transdermal lidocaine.
Clinical interpretation: Clinical warning signal
Limitations and uncertainties: No concentration measurement or isolated causality; THC percentage is not dose, not a CBD isolate.
Original sources for this finding: Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs. [CA_P_39502532]
CBD – laboratory and animal studies
Finding ID: B0321
Type of result: Direct preclinical investigation of the pair
Observation: CBD abolished the protective aripiprazole effect on social recognition in a rat model.
Mechanism: Behavioural modulation in an NMDA-antagonist model
Study type: MK-801 model, rats
Context studied: Direct CBD–aripiprazole co-administration; activity-related artefacts investigated.
Clinical interpretation: No confirmed attenuation of effect in humans
Limitations and uncertainties: One behavioural surrogate, not a pharmacokinetic measurement or transferable dose; not general antipsychotic failure.
Original sources for this finding: MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. [BMED26287433]
D8THC – clinical signals
Finding ID: B0322
Type of result: Treatment of a reported consequence of intoxication; not a simultaneous pair interaction
Observation: Psychosis improved after starting aripiprazole.
Mechanism: Treatment after suspected Delta8 intoxication
Study type: Man in his twenties after a Delta8 gummy product
Context studied: Aripiprazole 10 mg/day; apparent improvement within 4 days.
Clinical interpretation: Treatment case, not an interaction with co-administration
Limitations and uncertainties: Product history rather than chemical confirmation; natural resolution possible; no pharmacokinetic evidence.
Original sources for this finding: Clinical Diagnosis and Management of Gradual Onset Cannabis-Induced Psychosis Following the Consumption of Delta-8-Tetrahydrocannabinol. [BMED38571826]
Cannabis, non-standardised composition – clinical signals
Finding ID: B0323
Type of result: Treatment context; no direct evidence of a drug–drug interaction
Observation: A single case and cohorts reported symptom/relapse improvement, but not always reduced use.
Mechanism: Treatment context in cannabis use disorder/cannabis psychosis
Study type: Single case and registry/treatment-comparison data
Context studied: One 22-year-old receiving 10 mg/day without reduced use; registries distinguish oral/long-acting injections. Mixed-substance BeSt InTro cohort without a general change in effect.
Clinical interpretation: No isolated pair interaction
Limitations and uncertainties: Several data sources, with probably overlapping registry analyses in part; neither causal cannabinoid synergy nor proof of safety.
Original sources for this finding: Aripiprazole for treating cannabis-induced psychotic symptoms in ultrahigh-risk individuals. [BMED23673914]; Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder. [BMED39819543]; Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis. [BMED40326094]; Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study. [BMED38534050]; Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis. [BMED37861990]; Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study. [BMED41581246]; Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study. [BMED37269769]
References and access status
[V2_LABEL_D0123] ARIPIPRAZOLE (ARIPIPRAZOLE) TABLET [A-S MEDICATION SOLUTIONS]
Original source / bibliographic reference
Authors: A-S Medication Solutions
Year: 2026
Source type: Official US SPL / DailyMed
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
[CA_P_39502532] Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.
Original source / bibliographic reference
Authors: Chrobak AA, Woroń J, Siwek M.
Year: 2024
Source type: research-article; Journal Article
DOI: 10.3389/fphar.2024.1500312
PMID: 39502532
Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.
Bibliographic attribution or source identity cross-checked.
DOI – publisher access (access restrictions may apply)
PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.
Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.
[BMED26287433] MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol.
Original source / bibliographic reference
Authors: Deiana S, Watanabe A, Yamasaki Y, Amada N, Kikuchi T, Stott C, Riedel G.
Year: 2015
Source type: Publication; title and abstract reviewed
DOI: 10.1097/fbp.0000000000000178
PMID: 26287433
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED38571826] Clinical Diagnosis and Management of Gradual Onset Cannabis-Induced Psychosis Following the Consumption of Delta-8-Tetrahydrocannabinol.
Original source / bibliographic reference
Authors: Denton EE, Jung SS, Ventura CAI.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.7759/cureus.55464
PMID: 38571826
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED23673914] Aripiprazole for treating cannabis-induced psychotic symptoms in ultrahigh-risk individuals.
Original source / bibliographic reference
Authors: Rolland B, Geoffroy PA, Jardri R, Cottencin O.
Year: 2013
Source type: Publication; title and abstract reviewed
DOI: 10.1097/wnf.0b013e3182908330
PMID: 23673914
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED39819543] Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder.
Original source / bibliographic reference
Authors: Trovini G, Lombardozzi G, Kotzalidis GD, Pagano I, Amici E, Giovanetti V, Perrini F, Fagiolini A, De Filippis S.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.2174/011570159x350599241214042724
PMID: 39819543
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED40326094] Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.
Original source / bibliographic reference
Authors: Mustonen A, Taipale H, Denissoff A, Ellilä V, Di Forti M, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J, Niemelä S.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.1192/bjp.2025.72
PMID: 40326094
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED38534050] Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study.
Original source / bibliographic reference
Authors: Denissoff A, Taipale H, Tiihonen J, Di Forti M, Mittendorfer-Rutz E, Tanskanen A, Mustonen A, Niemelä S.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.1093/schbul/sbae034
PMID: 38534050
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED37861990] Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.
Original source / bibliographic reference
Authors: Thurstone C, Loh R, Foreman K, Thurstone CA, Wolf C.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.1089/cap.2023.0053
PMID: 37861990
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED41581246] Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.
Original source / bibliographic reference
Authors: Mustonen A, Niemelä S, Denissoff A, Forti MD, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J, Taipale H.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.psychres.2026.116966
PMID: 41581246
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED37269769] Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study.
Original source / bibliographic reference
Authors: Alisauskiene R, Johnsen E, Gjestad R, Kroken RA, Kjelby E, Sinkeviciute I, Fathian F, Joa I, Reitan SK, Rettenbacher M, Løberg EM.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.genhosppsych.2023.05.003
PMID: 37269769
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.
Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility
Aripiprazole and cannabinoids: documented findings, evidence, sources and data gaps. Research information for discussion with your doctor or pharmacist.